Fagron strengthens its market positioning with the acquisitions of CareFirst in North America and Injeplast in Brazil
January 07 2025 - 12:00AM
UK Regulatory
Fagron strengthens its market positioning with the acquisitions of
CareFirst in North America and Injeplast in Brazil
Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 7 Jan 2025 – 7AM
CET
Fagron strengthens its market positioning with the
acquisitions of CareFirst in North America and Injeplast in
Brazil
Fagron, the leading global player in pharmaceutical compounding
is pleased to announce the signing of two strategic acquisitions:
CareFirst Specialty Pharmacy in North America and Injeplast in
Brazil. These acquisitions underscore Fagron’s commitment to
expanding across our key markets whilst adhering to our disciplined
acquisition strategy.
The combined enterprise value of these two acquisitions is
c.€30m and are fully financed through Fagron’s own resources and
remain subject to customary clearances. Both businesses operate
with an EBITDA margin slightly above Fagron’s existing group
margin.
CareFirst Specialty Pharmacy, based in New Jersey, USA,
is a 503A pharmaceutical compounder specializing in the health
& wellness sector. It provides non-sterile medication through
patient-specific prescriptions, with a particular focus on hormone
replacement therapy and dermatology.
With mid-single digit (€m) in annual revenue, Carefirst enhances
Fagron’s footprint in North America’s prevention and lifestyle
markets. This acquisition enables Fagron to meet increasing demand
for personalized healthcare solutions and reinforces its leadership
in this growing segment.
Injeplast, located in São Paulo, Brazil, is a
GMP-certified, vertically integrated producer of plastic packaging.
With low double digit (€m) in annual revenue, the company offers
high-quality packaging solutions and efficient manufacturing
processes.
This acquisition supports Fagron’s Essentials strategy by
broadening its product portfolio and customer base in Latin
America. Additionally, Injeplast’s capabilities will extend
Fagron’s support to other regions, further enhancing global
operations.
In addition, the EuroOTC acquisition announced during Q3
2024 trading update has now closed.
Rafael Padilla, CEO of Fagron commented: “We are
incredibly pleased to announce these two acquisitions, which
reflect our disciplined and strategic growth approach. The
acquisition of CareFirst allows us to meet the increasing demand in
the prevention and lifestyle segments, reinforcing our leadership
in North America. Similarly, the addition of Injeplast will
strengthen our market positioning in Latin America by broadening
our product portfolio and expanding our customer base. Both
businesses align with Fagron’s Group margin, and we expect to
integrate them over the next 18 to 24 months.”
Financial calendar 2025
20 February 2025 Full year results 2024
10 April Trading update first quarter 2025
12 May 2025 Annual shareholders meeting
31 July Half year results 2025
9 October Trading update third quarter 2025
Results and trading updates are published at 7.00 AM CET
Further information
Karin de Jong
Chief Financial Officer
investors@fagron.com
About Fagron
Fagron is a leading global company active in pharmaceutical
compounding, focusing on delivering personalized medicine to
hospitals, pharmacies, clinics and patients in more than 30
countries around the world.
Belgian company Fagron NV has its registered office in Nazareth
and is listed on Euronext Brussels and Euronext Amsterdam under the
ticker symbol ‘FAGR’. Fagron’s operational activities are managed
by the Dutch company Fagron BV, which is headquartered in
Rotterdam.
Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be
forward-looking. Such forward-looking statements are based on
current expectations and are influenced by various risks and
uncertainties. Consequently, Fagron cannot provide any guarantee
that such forward-looking statements will, in fact, materialize and
cannot accept any obligation to update or revise any
forward-looking statement as a result of new information, future
events or for any other reason.
In the event of differences between the English translation
and the Dutch original of this press release, the latter
prevails.
- Fagron strengthens its market positioning with the acquisitions
of CareFirst in North America and Injeplast in Brazil
Fagron NV (TG:4A5)
Historical Stock Chart
From Dec 2024 to Jan 2025
Fagron NV (TG:4A5)
Historical Stock Chart
From Jan 2024 to Jan 2025
